Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

MLA

Uy, Geoffrey L., et al. “Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.” Blood, vol. 137, no. 6, Feb. 2021, pp. 751–62. EBSCOhost, https://doi.org/10.1182/blood.2020007732.

APA

Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., Ravandi, F., Erba, H. P., Byrne, M., Michaelis, L., Topp, M. S., Vey, N., Ciceri, F., Carrabba, M. G., Paolini, S., … DiPersio, J. F. (2021). Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 137(6), 751–762. https://doi.org/10.1182/blood.2020007732

Chicago

Uy, Geoffrey L., Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, et al. 2021. “Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.” Blood 137 (6): 751–62. doi:10.1182/blood.2020007732.